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Clinical trialBackground: Under the auspices of the World Health Organization (WHO) Global Action Plan, PATH
supported evaluation of a trivalent, seasonal inactivated influenza vaccine candidate produced by the
Institute of Vaccines and Medical Biologicals (IVAC), a Vietnamese manufacturer.
Methods: In 2015, 60 healthy adult subjects 18–45 years of age were enrolled in a Phase 1, single center,
double blind, randomized, placebo-controlled study conducted at a district health center in Thai Binh
Province, Vietnam. The study evaluated the overall safety and immunogenicity of a seasonal, trivalent
inactivated split virion influenza vaccine. Volunteers were given either vaccine or placebo in a random-
ized 1:1 ratio.
After undergoing screening, eligible volunteers provided their signed consent and were enrolled in the
study. On the first day of immunization, randomly chosen volunteers received IVACFLU-S 15 lg (mcg)
hemagglutinin of each of the three strains in 0.5 mL or placebo by intramuscular injection. All volunteers
were monitored for adverse events and underwent blood testing at screening and Day 8 to assess the vac-
cine candidate’s safety. Sera obtained before and 21 days after immunization were tested for influenza
antibody titers using the hemagglutination-inhibition (HAI) and microneutralization tests (MNT).
Results: Vaccine was well tolerated, and there were no serious adverse events reported. HAI and MNT
identified serum antibody responses against the three influenza strains in nearly all volunteers who
received the vaccine. Overall, serum HAI responses of fourfold or greater were observed in 93 percent,
83 percent, and 77 percent of H1, H3, and B strains, respectively. Seroprotection rates were also very high.
Conclusions: IVAC’s seasonal, trivalent influenza vaccine was safe and well tolerated and induced high
levels of seroconversion and seroprotection rates. These clinical data are a first step towards demonstrat-
ing the feasibility of producing the vaccine locally and that seasonal vaccine production in Vietnam may
be an effective strategy for enhancing the global influenza vaccine supply. ClinicalTrials.gov number
NCT02598089, October 15, 2015.
 2016 Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).1. IntroductionInfluenza is one of the most significant infectious disease
threats to humans worldwide [1]. It affects individuals of all ages,
causes repeated infections throughout life, and is responsible for
recurrent seasonal epidemics as well as periodic global pandemics
of varying severity [2]. In most people, influenza causes mild to
severe respiratory illness; however, in vulnerable populations it
can occasionally lead to death. The seriousness of influenza in
young children, older adults, pregnant women, and people with
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countries have in place recommendations to vaccinate such indi-
viduals every year.
A distinct feature of influenza virus is its ability to mutate, lead-
ing to antigenic changes that require the introduction of new vac-
cines each year. Seasonal changes in the surface glycoproteins,
hemagglutinin, and neuraminidase, enable influenza viruses to
evade immunity the body may have developed against previously
circulating strains. For this reason, natural infection or vaccination
are generally only protective for one influenza season. Evolutionary
pressures lead to the emergence of new influenza strains, for which
there is decreased immunity in the population.
There is mounting evidence to suggest that the burden of influ-
enza among young children is particularly high in low-income,
tropical regions with high population densities. Multiple epidemi-
ological studies from several low-resource countries have con-
firmed that influenza-associated pneumonia is linked with
substantial morbidity in young children [3–5]. Vaccination is the
most effective way to decrease respiratory disease in this high-
risk age group.
Clinical studies have demonstrated a substantial burden of
influenza disease in many resource-constrained settings. While
global disease burden data are not well tracked, an estimated
500,000–3.5 million deaths across all age groups are associated
with annual influenza outbreaks [6]. In 2008, nearly one million
new episodes of influenza-associated severe acute lower respira-
tory infection necessitating hospital admission were estimated to
have occurred in children younger than 5 years of age worldwide
[3]. Influenza surveillance data in Vietnam between 2006 and
2011 indicated that, of 29,499 respiratory specimens tested, 5241
(18 percent) were positive for the virus [7].
Vaccines are central both to the effective control of seasonal
outbreaks and to pandemic preparedness. Since 2006, WHO,
together with governments, the pharmaceutical industry, and
other stakeholders, has been implementing the global pandemic
influenza action plan in order to increase vaccine supply around
the world [8]. Building influenza vaccine development capacity in
low-resource countries is an integral part of this plan, as well as
research and development into more efficacious technologies, such
as those that allow significant dose-sparing. To this end, WHO
launched the influenza vaccine technology transfer initiative in
2007. To date, vaccine manufacturers in 14 developing countries
have received grants that help to provide increased production
capacity of inactivated or live attenuated influenza vaccine for
their populations. Additionally, WHO established a centralized
hub in order to train country scientists and regulators on the
new technologies [9].
Manufacturers around the globe have tested various seasonal,
trivalent influenza vaccine candidates in healthy adults and use
them yearly before the influenza season. Seasonal influenza vac-
cine development is guided by the WHO Global Action Plan for
Influenza Vaccines (GAP), an initiative to support development of
new influenza vaccines, increase demand for seasonal vaccines,
and enhance influenza vaccine production capacity [9]. With sup-
port from international donors, including the Biomedical Advanced
Research and Development Authority (BARDA) of the US Depart-
ment of Health and Human Services, the WHO leads a program
to support influenza vaccine manufacturers in low-resource coun-
tries that is crucial to increasing overall manufacturing capacity as
well as enhancing regional access to vaccines. In the first phase of
the plan, the WHO provided funding and assistance to manufactur-
ers in six countries, including Vietnam, to establish influenza vac-
cine production capacity.
The GAP program is designed to meet the needs of low-resource
countries for pandemic and seasonal influenza vaccines [9]. IVAC
became a member of the program in 2006 and since that timehas developed a manufacturing facility and a chicken farm capable
of producing eggs for influenza vaccine production [10]. We report
in this paper the safety and immune response of the first seasonal
vaccine produced by IVAC in Vietnam.2. Materials and methods
IVACFLU-S is a trivalent, seasonal, inactivated split virion influ-
enza vaccine containing 15 lg (mcg) hemagglutinin (HA) of each of
three strains (A/H1N1, A/H3N2, and B) in 0.5 mL of phosphate
buffered saline, pH 7.2. The trivalent seasonal inactivated, split
virion influenza vaccine (IVACFLU-S) contains 15 lg (mcg) HA of
each of the three strains in 0.5 mL of phosphate buffered saline
(PBS), pH 7.2. The vaccine used in this trial contained the strains
recommended for the 2014–15 Northern Hemisphere: A/Califor-
nia/7/2009 (H1N1) pdm09, A/Texas/50/2012 (H3N2), B/Mas-
sachusetts/2/2012. The placebo (PBS) was manufactured by IVAC.
PBS, pH 7.2, was also in 0.5 ml single-dose vials. The vaccine and
placebo were examined for quality control by the National Insti-
tute of Control Vaccine and Medical Biologicals and were granted
the certificate of quality that met the requirements on physical
properties, pH, aluminum concentration, protein concentration,
potency, identity, general safety, endotoxin, and sterility. Study
materials were prepared, coded, and blinded at IVAC by
pharmacists who were not involved in study operations. Coded
vaccine and placebo were provided to the site and dispensed to
study subjects according to the sequential randomization code by
blinded study staff. The vaccine candidate and placebo were
administered at a final volume of 0.5 mL by deep, intramuscular
injection in the deltoid muscle.
2.1. Volunteers
Volunteers were 18–45 years of age and healthy as ascertained
by medical history, physical examination, and laboratory analysis.
Women of childbearing potential were required to submit a nega-
tive pregnancy test and commit to using adequate contraception.
Volunteers with active medical conditions, known allergies to the
study medication, or abnormal screening laboratory tests (HCV
and HBV, WBC, hemoglobin, platelets, bilirubin, ALT, creatinine,
and total protein) were excluded.
2.2. Study design
This is a Phase 1, single center, double blind, randomized,
placebo-controlled study. The primary objective of the study was
to evaluate the safety profile of one intramuscular dose of the vac-
cine, the secondary objective was to evaluate its immunogenicity.
Sixty healthy male and female adults, 18–45 years of age, partici-
pated in the trial. Thirty volunteers were randomly selected to
receive the vaccine candidate, while the remaining 30 received pla-
cebo. The study took about five months to complete, with each vol-
unteer involved for three months from the day of injection. To
address any potential serious adverse events, the Preventative
Medicine Center (PMC) of Thai Binh province and District Health
Center (DHC) of Hung Ha district, in collaboration with Vietnam’s
National Institute of Hygiene and Epidemiology (NIHE), established
a process of coordinating care. Personnel and equipment at the dis-
trict hospital met Ministry of Health requirements for medical care,
as well as emergency care, for unexpected adverse events in this
trial.
Volunteers went through two screening visits: the first occurred
between 5 and 30 days before vaccination and the second occurred
just prior to vaccination. Fully eligible volunteers had to demon-
strate verbal understanding of the study purpose, procedures,
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lected blood specimens for immunological testing prior to vaccina-
tion. Study product was masked so neither staff nor volunteers
were aware of product allocation. Study staff then carefully moni-
tored volunteers for adverse reactions during the 30 min following
vaccination.
In the first week following vaccination, volunteers were asked to
record local and systemic signs and symptoms and note concomi-
tant medications. Clinical investigation team member visited vol-
unteers in-person on Day 2 and either visited or called on Day 6
(one and five days after vaccination) to check on well-being and
confirm that volunteers were correctly completing the diary card.
Volunteers returned to the study clinic several days after vacci-
nation for review their diary cards and report any adverse events
with study staff. They also provided blood samples for biochemical
and hematological testing; the study physician reviewed results
within 36 h of receipt and determined the severity grade using a
grading system for adverse events. The physician followed any
results Grade 2 or higher - considered to be clinically significant
- until resolution or stabilization.
Volunteers returned to the study clinic three weeks after vacci-
nation, at which time study staff reviewed interim medical histo-
ries and concomitant medications with the participant and
collected final blood specimens for immunogenicity analyses.
The last interaction with volunteers occurred by phone on Day
91 for (a) closure of any ongoing adverse events and concomitant
medications; and (b) collection of any serious adverse event
(SAE). Finally, volunteers were offered a free licensed, seasonal
influenza vaccine, if still within influenza season.
The Protocol Safety Review Team monitored clinical operations
for safety throughout the trial. This team conducted regular (gen-
erally weekly) reviews of safety events through Day 22 of the study
and ad hoc after Day 22 upon request of the principal investigator
or study medical officer. Solicited systemic reactions included
fever, headache, joint pain, fatigue, muscle aches, chills, and
increased sweating.Table 12.3. Laboratory assays
Blood was collected for clinical chemistries at screening and
Day 8 (seven days after vaccination). Laboratory analysis included
WBC, hemoglobin, platelets, bilirubin, ALT, creatinine and total
protein.
HAI assay: Testing was performed at NIHE on pre-vaccination
and Day 22 post-vaccination serum samples for antibody to the
three influenza vaccine strains microtiter HAI using standard
methods [11]. The serum HAI titer was the reciprocal of the serum
dilution in the last well with complete hemagglutination inhibi-
tion. Serum samples with no reactivity at 1:10 were assigned a
value of 1:5.
Microneutralization (MN) assay: Serum samples (pre-
vaccination and Day 22) were also assayed for neutralizing anti-
body by MN assay as described previously [11]. The neutralizing
antibody titer was the reciprocal of the serum dilution resulting
in 50% drop in viral antigen (nucleoprotein) as detected by ELISA.
The geometric mean titers (GMT) and corresponding confidence
intervals were based on a log 10 scale. Exact confidence intervals
were reported for all proportion estimates.Demographic characteristics of subjects participating in the IVACFLU-S phase 1 trial.
Characteristic Statistic Vaccine
(N = 30)
Placebo
(N = 30)
Total
(N = 60)
Sex
Male n (%) 3 (10.0) 9 (30.0) 12 (20.0)
Female n (%) 27 (90.0) 21 (70.0) 48 (80.0)
Age (Years) Mean 37.7 37.8 37.82.4. Statistical analyses
The vaccine safety profile was assessed according to the number
and percentage of volunteers with solicited local and general reac-
tions during the seven days post-injection; unsolicited adverse
events over the 21-day post-vaccination period; adverse changesin clinical laboratory parameters; and any serious adverse events
that occur over the entire study period.
Immunogenicity assessments included: Number and percent-
age of subjects with a pre-vaccination titer greater than or equal
to 1:40 (baseline titer); number and percentage of subjects with
a serum HAI antibody titer greater than or equal to 1:40 to each
of the three vaccine components measured on Day 22 post-
vaccination (seroprotection); number and percentage of subjects
with fourfold rise from baseline and a titer greater than or equal
to 1:40 against each of the influenza vaccine strain-specific H1,
H3, and, B on Day 22 post-vaccination by HAI and MNT; and geo-
metric mean neutralization titers of neutralizing antibodies
(MNT) pre- (Day 1) and post-vaccination (Day 22) for each of the
three antigens.
Seroconversion was defined as a serum HAI titer meeting the
following criteria: (1) Pre-vaccination titer less than 1:10 and a
post-vaccination titer greater than or equal to 1:40; or (2) Pre-
vaccination titer greater than or equal to 1:10 and at least a four-
fold increase in post-vaccination measured on Day 22. Geometric
mean titers of serum HAI antibodies pre- (Day 1) and post-
vaccination (Day 22) for each of the three antigens. Geometric
mean fold rises of serum (HAI) antibodies (post-vaccination/pre-v
accination) for each of the three antigens.
Statistical analyses were performed at the two-sided signifi-
cance level of a = 0.05, unless otherwise stated. No adjustments
were made for multiple statistical testing. All programs for data
output and analyses were written in SAS version 9.1 (SAS Insti-
tute, Cary, NC).
Safety and tolerability analyses included all volunteers and used
descriptive statistics. Chi-square tests for categorical data and
analysis of variance for continuous data was used to determine dif-
ferences in baseline characteristics. Primary safety measures
included frequency of vaccination site abnormalities; incidence
of local and systemic adverse events and their relationship to the
study drug; and changes in clinical laboratory results, vital signs,
and physical examination findings. Reaction rates were compared
using Fisher’s Exact and Cochran Mantel-Haenszel methods.3. Results
A total of 107 volunteers were screened and 60 volunteers were
randomized and vaccinated in November, 2015, and all 60 volun-
teers completed the trial. Females predominated in both vaccine
and placebo groups, however there was a higher proportion of
females in the vaccine group. Participants’ mean age was
37.8 years of age and was similar in both vaccine and placebo
groups (Table 1).3.1. Reactogenicity
Vaccine was generally well tolerated, and there were no serious
adverse events reported (Table 2). Mild to moderate local and sys-
temic adverse events were reported, with pain and tenderness at
the site of vaccination being most common, reported in more than
half of all volunteers (and reported more frequently in the vaccine
Table 2
Numbers of subjects (%) experiencing local or systemic adverse events by highest severity collected in the 7 days after injection.
Solicited Vaccine (n = 30) Placebo (n = 30)
Adverse event Mild
n (%)
Moderate
n (%)
Severe
n (%)
Mild
n (%)
Moderate
n (%)
Severe
n (%)
Injection pain 17 (57) 2 (7) 0 5 (17) 0 0
Tenderness 16 (53) 1 (3) 0 9 (30) 0 0
Induration 0 1 (3) 0 0 0 0
Swelling 0 1 (3) 0 0 0 0
Headache 6 (20) 1 (3) 0 8 (27) 1 (3) 0
Tiredness 5 (17) 2 (7) 0 6 (20) 1 (3) 1 (3)
Chills 2 (7) 0 0 3 (10) 1 (3) 0
Muscle aches 3 (10) 0 0 4 (13) 1 (3) 0
Vomiting 1 (3) 0 0 1 (3) 0 0
Joint aches 0 1 (3) 0 1 (3) 0 1 (3)
Nausea 0 0 0 3 (10) 0 0
Temperature 0 0 0 0 0 0
Severity ratings: mild – noticeable but with no effect on activities, moderate – interferes with daily activities, severe – adverse events prevent daily activities. Temperature
grade 0 or none is <37.7 C.
Table 3
GMT antibody response to influenza H1, H3 and B by HAI test for vaccine and placebo.
GMT
H1
95%CI GMT
H3
95%CI GMT
B
95%CI
Vaccine
Day 1 10 (6.7, 15.0) 39.5 (22.9, 68.4) 8.8 (6.7, 11.6)
Day 22 371.9 (245.4, 563.6) 640 (419.2, 977.1) 68.1 (47.1, 98.2)
Fold 37.2 (23.7, 58.3) 16.2 (9.2, 28.4) 7.7 (5.0, 12.1)
Placebo
Day 1 10.6 (7.1, 15.7) 35.6 (21.8, 58.3) 6.9 (5.8, 8.2)
Day 22 10.7 (7.2, 15.9) 33.6 (21.6, 52.4) 7 (5.9, 8.3)
Fold 1 (1.0, 1.0) 0.9 (0.9, 1.0) 1 (0.9, 1.1)
Table 4
GMT antibody response to influenza H1, H3 and B by MNT for vaccine and placebo.
GMT
H1
95%CI GMT
H3
95%CI GMT
B
95%CI
Vaccine
Day 1 8.7 (6.0, 12.5) 38.6 (22.4, 66.8) 16.2 (10.3, 25.6)
Day 22 417.4 (263.0, 662.4) 670.3 (405.9, 1106.7) 201.6 (123.6, 328.8)
Fold 47.9 (29.1, 79.0) 17.3 (9.7, 31.0) 12.4 (6.9, 22.3)
Placebo
Day 1 10.8 (7.3, 16.1) 40 (23.5, 68.1) 14.6 (10.4, 20.6)
Day 22 10.5 (7.2, 15.3) 39.1 (23.1, 66.2) 14.3 (10.2, 20.0)
Fold 1 (0.9, 1.0) 1 (0.9, 1.0) 1 (0.9, 1.0)
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less commonly reported and occurred at about the same rate as
in the placebo recipients. Headache and tiredness, usually mild,
were the most commonly recorded systemic symptoms, occurring
with equal frequency in the vaccine and placebo groups.
Two volunteers reported severe systemic adverse events in the
seven days following infection. One subject reported severe fatigue
and another had severe joint aches. Both subjects had received the
placebo. The highest temperature recorded was 37.4 C (99.3 F).
Thirteen (22%) of 60 subjects reported an oral temperature of
greater than 37 C (range 37.1–37.4 C).
3.2. Immunogenicity
The geometric mean titers rose in the vaccine group for all three
antigens tested by HAI and in the MN test (Tables 3 and 4). The
highest GMT was observed for H3 and the highest fold rise hap-
pened for H1. The GMT for B was the lowest, but still showed a7.7-fold increase going from 8.8 to 68.1. The MN test showed sim-
ilar trends.
The highest percentage of subjects with pre-vaccination titers
greater than or equal to 40 was for H3 where approximately half
of all subjects in both the vaccine and placebo groups had elevated
titers by either HAI or MN tests (Table 5). In contrast, 15–20 per-
cent of subjects had pre-existing elevated titers to H1 by both
HAI and MN tests. Elevated titers to the B strain were observed
in less than 10 percent of subjects by HAI test. In contrast, elevated
titers were observed in more than 30 percent of subjects when sera
tested by MN test.
Seroconversion was observed in the majority of vaccinated sub-
jects with 93 percent for H1, 83 percent for H3, and 77 percent for
B (Table 6). Similar responses were observed in the MN test. Sero-
conversion, defined as a post-vaccination titer greater than or
equal to 40, was observed in more than 90 percent of vaccinated
subjects by both HAI and MN tests. Seroprotection rates were also
very high. By HAI 29 (97 percent) of 30 vaccinated individuals had
Table 7
Seroprotection rates (TiterP 40) by HAI and MNT measured 21 days after
immunization.
HAI MNT
n, % 95%CI n, % 95%CI
Vaccine (n = 30)
A/H1N1 29 (96.7) (82.8, 99.9) 29 (96.7) (82.8, 99.9)
A/H3N2 29 (96.7) (82.8, 99.9) 29 (96.7) (82.8, 99.9)
B 28 (93.3) (77.9, 99.2) 26 (86.7) (69.3, 96.2)
Placebo (n = 30)
A/H1N1 6 (20.0) (7.7, 38.6) 5 (16.7) (5.6, 34.7)
A/H3N2 16 (53.3) (34.3, 71.7) 14 (46.7) (28.3, 65.7)
B 0 (0.0) (0.0, 11.6) 9 (30.0) (14.7, 49.4)
Table 5
Baseline titer P40 by HAI and MNT for vaccine and placebo recipients.
HAI MNT
n (%) 95%CI n (%) 95%CI
Vaccine (n = 30)
A/H1N1 5 (16.7) (5.6, 34.7) 4 (13.3) (3.8, 30.7)
A/H3N2 16 (53.3) (34.3, 71.7) 16 (53.3) (34.3, 71.7)
B 3 (10.0) (2.1, 26.5) 11 (36.7) (19.9, 56.1)
Placebo (n = 30)
A/H1N1 6 (20.0) (7.7, 38.6) 5 (16.7) (5.6, 34.7)
A/H3N2 16 (53.3) (34.3, 71.7) 15 (50.0) (31.3, 68.7)
B 0 (0.0) (0.0, 11.6) 9 (30.0) (14.7, 49.4)
Table 6
Seroconversion rates by HAI and MNT for vaccine and placebo recipients.
HAI MNT
n (%) 95% CI n (%) 95% CI
Vaccine (n = 30)
A/H1N1 28 (93.3) (77.9, 99.2) 28 (93.3) (77.9, 99.2)
A/H3N2 25 (83.3) (65.3, 94.4) 25 (83.3) (65.3, 94.4)
B 23 (76.7) (57.7, 90.1) 21 (70.0) (50.6, 85.3)
Placebo (n = 30)
A/H1N1 0 (0.0) (0.0, 11.6) 0 (0.0) (0.0, 11.6)
A/H3N2 0 (0.0) (0.0, 11.6) 0 (0.0) (0.0, 11.6)
B 0 (0.0) (0.0, 11.6) 0 (0.0) (0.0, 11.6)
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cent) of 30 vaccinated individuals had sero-protective titers
against the B strain (Table 7). Serological analysis in 60 subjects
showed a close correlation between HAI and MN tests.4. Discussion
Despite increasing recognition of influenza’s importance in the
acute respiratory infection burden in low-resource countries, the
complex and specialized production methods can pose a significant
barrier to local production and widespread use in many low- and
middle-income countries. Influenza vaccine production in Vietnam
may be a useful strategy for expanding influenza vaccination to
these settings, significantly reducing respiratory illnesses and time
away from work. Protection from influenza through vaccination
may improve a country’s or a region’s capacity for continued
growth and development. The high baseline titers, particularly to
the recently circulating H3 strain in over half of the study subjects,
suggest that influenza is widespread in Vietnam. This is supported
by the influenza surveillance report from WHO for seasonal influ-
enza in Vietnam that shows A(H1N1)pdm09 predominant in weeks
8–14, with A(H3) predominant weeks 17–29, and then B strainspredominant both early in 2014 (weeks 7–16), and then again later
in 2014 (weeks 38–47) [12].
In this study, the IVACFLU-S vaccine was a safe and immuno-
genic trivalent influenza vaccine in adults 18–45 years old. Reacto-
genicity data indicate the vaccine was well tolerated. Most subjects
had no symptoms or mild to moderate arm pain and headache. No
SAEs were reported.
Serological analysis in 60 volunteers showed a close correlation
between HAI and MN tests. There did not appear to be an advan-
tage to using both tests. Considering that similar results were
obtained, future clinical studies of this vaccine will just focus on
the HAI assay, which is the method favored by regulators. The high
rate of subjects with elevated pre-vaccination titers to H3 suggests
substantial H3N2 epidemic activity at the study site in recent influ-
enza seasons prior to the study. GMTs for HAI and MNT showed a
strong response to all three strains. Seroconversion rates were
greater than 90 percent for H1, greater than 80 percent for H3,
and greater than 70 percent for B by the HAI and MNassays. Sero-
protection rates by HI were 97 percent for H3 and H1, and 93 per-
cent for B. IVACFLU-S was safe and immunogenic, comparing
favorably to other commercially available influenza vaccines
[13,14].
In this Phase 1 study in small numbers of healthy young adults,
IVACFLU-S met the US Food and Drug Administration and Euro-
pean Medicines Agency guidelines for seasonal influenza vaccines,
meeting the lower bound of the two-sided 95% confidence inter-
vals for seroconversion for HAI antibody (P40%) and for seropro-
tection (P70%) for all three influenza strains [15]. These data
justify larger trials in a broader cross-section of the Vietnamese
population that would lead to licensure of the IVAC vaccine for
domestic market. Annual seasonal vaccine production by a domes-
tic manufacturer would decrease the dependence on purchase
from international markets, provide domestic source for seasonal
vaccines, and also allow production of pandemic vaccines locally
should the need arise.Funding and acknowledgements
We appreciate the work of John Donnelly for his dedication to
this program and Iksung Cho for his work on protocol develop-
ment. We would like to thank NIHE Clinical Trial Unit, NIHE Influ-
enza Lab, Thai Binh Preventive Medicine Center, Hung Ha District
Health Center, Chi Hoa Commune Health Center, and IVAC. We
are also indebted to the staff at PATH US and PATH Vietnam for
clinical coordination, and to Katie Regan for editing the manu-
script. We would also like to thank the sponsors of the trial: Erin
Sparrow and Martin Friede, Technology Transfer Initiative, WHO,
Geneva, Switzerland; Sheng Li, The Biomedical Advanced Research
and Development Authority (BARDA), U.S. Department of Health
and Human Services; Samantha Hew at Quintiles, Malaysia, for
clinical project coordination; and Suman Kapoor at Quintiles, India,
for data management services.
Financial support for the study was provided to PATH from the
US Department of Health and Human Services/BARDA (Grant No. 6
IDSEP130018-01-06).Conflict of interest
Authors declare no conflicts of interest.References
[1] Fineberg HV. Pandemic preparedness and response–lessons from the H1N1
influenza of 2009. N Engl J Med 2014;370:1335–42.
5462 D.D. Anh et al. / Vaccine 34 (2016) 5457–5462[2] Lafond KE, Nair H, Rasooly MH, Valente F, Booy R, Rahman M, et al. Global role
and burden of influenza in pediatric respiratory hospitalizations, 1982–2012: a
systematic analysis. PLoS Med 2016;13:e1001977.
[3] Nair H, Brooks WA, Katz M, Roca A, Berkley JA, Madhi SA, et al. Global burden
of respiratory infections due to seasonal influenza in young children: a
systematic review and meta-analysis. Lancet 2011;378:1917–30.
[4] Walker CL, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA, et al. Global
burden of childhood pneumonia and diarrhoea. Lancet 2013;381:1405–16.
[5] Brooks WA, Goswami D, Rahman M, Nahar K, Fry AM, Balish A, et al. Influenza
is a major contributor to childhood pneumonia in a tropical developing
country. Pediatr Infect Dis J 2010;29:216–21.
[6] Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and
regional mortality from 235 causes of death for 20 age groups in 1990 and
2010: a systematic analysis for the Global Burden of Disease Study 2010.
Lancet 2012;380:2095–128.
[7] Saha S, Chadha M, Al MA, RahmanM, Sturm-Ramirez K, Chittaganpitch M, et al.
Influenza seasonality and vaccination timing in tropical and subtropical areas
of southern and south-eastern Asia. Bull World Health Organ 2014;92:318–30.
[8] World Health Organization. Global pandemic influenza action plan to increase
vaccine supply; 2006.
[9] Friede M, Palkonyay L, Alfonso C, Pervikov Y, Torelli G, Wood D, et al. WHO
initiative to increase global and equitable access to influenza vaccine in theevent of a pandemic: supporting developing country production capacity
through technology transfer. Vaccine 2011;29(Suppl 1):A2–7.
[10] Hoa LK, Hiep LV, Be LV. Development of pandemic influenza vaccine
production capacity in Viet Nam. Vaccine 2011;29(Suppl 1):A34–6.
[11] Kendal A, Pereira M, Skehel J. Concepts and procedures for laboratory-based
influenza surveillance. US Department of Health and Human Services; 1982.
[12] WHO FluNet, Influenza Laboratory Suveillance Information by the Global
Influenza Surveillance and Response System (GISRS) (www.who.int/flunet)
<http://gamapserver.who.int/gareports/Default.aspx?ReportNo=1>, [accessed
on 12 December 2014].
[13] Delore V, Salamand C, Marsh G, Arnoux S, Pepin S, Saliou P. Long-term clinical
trial safety experience with the inactivated split influenza vaccine, Vaxigrip.
Vaccine 2006;24:1586–92.
[14] Arnoux S, Weinberger C, Gessner BD. Vaccine-preventable influenza disease
burden from clinical trials of Vaxigrip – an inactivated split virion influenza
vaccine – supports wider vaccine use. Vaccine 2007;25:7720–31.
[15] US Department of Health and Human Services. Guidance for Industry: Clinical
Data Needed to Support the Licensure of Seasonal Inactivated Influenza
Vaccines. Rockville, MD: Food and Drug Administration; 2007. <http://www.
fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatory
Information/Guidances/Vaccines/ucm091990.pdf>.
